Listing 1 - 6 of 6 |
Sort by
|
Choose an application
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.
Medicine --- aflibercept monotherapy --- polypoidal choroidal vasculopathy --- neovascular age-related macular degeneration --- good baseline visual acuity --- ForeseeHome AMD Monitoring System® --- AREDS2-HOME study --- age-related macular degeneration --- exudation --- optical coherence tomography angiography --- anti-vascular endothelial growth factor --- brolucizumab --- epithelial tear --- optical coherence tomography --- Sorsby's fundus dystrophy --- Sorsby --- hereditary retinal dystrophy --- choroidal neovascularisation --- macular neovascularization --- anti-VEGF treatment --- long-term FU --- treatment outcome --- emerging treatment --- neovascular age-related macular degeneration (nAMD) --- Vascular Endothelial Growth Factor (VEGF) --- cataract surgery --- clinical trials --- real-world evidence --- AMD --- oct-angiography --- fellow eye --- choriocapillaris --- quiescent macular neovascularization --- ranibizumab --- aflibercept --- anti-VEGF --- visual acuity --- reading acuity --- disease activity --- treatment change --- treat and extend --- switch therapy --- retina --- choroidal neovascularization --- angiogenesis --- meteorin --- therapeutic innovation --- prevention --- nutrients --- lifestyle --- treatment-naive --- anti-vascular endothelial growth factor --- cardiovascular risk factors --- arterial hypertension --- macula-off rhegmatogenous detachment --- superficial perifoveal capillary plexus --- retinal deep perifoveal capillary plexus --- identification --- risk --- Delphi --- STARS® --- food supplement --- bevacizumab --- meta-analysis --- meta-regression --- age-related macular degeneration (AMD) --- comparative therapies --- effectiveness --- intravitreal anti-vascular endothelial growth factor --- treat-and-extend --- pro re nata regimen --- aflibercept monotherapy --- polypoidal choroidal vasculopathy --- neovascular age-related macular degeneration --- good baseline visual acuity --- ForeseeHome AMD Monitoring System® --- AREDS2-HOME study --- age-related macular degeneration --- exudation --- optical coherence tomography angiography --- anti-vascular endothelial growth factor --- brolucizumab --- epithelial tear --- optical coherence tomography --- Sorsby's fundus dystrophy --- Sorsby --- hereditary retinal dystrophy --- choroidal neovascularisation --- macular neovascularization --- anti-VEGF treatment --- long-term FU --- treatment outcome --- emerging treatment --- neovascular age-related macular degeneration (nAMD) --- Vascular Endothelial Growth Factor (VEGF) --- cataract surgery --- clinical trials --- real-world evidence --- AMD --- oct-angiography --- fellow eye --- choriocapillaris --- quiescent macular neovascularization --- ranibizumab --- aflibercept --- anti-VEGF --- visual acuity --- reading acuity --- disease activity --- treatment change --- treat and extend --- switch therapy --- retina --- choroidal neovascularization --- angiogenesis --- meteorin --- therapeutic innovation --- prevention --- nutrients --- lifestyle --- treatment-naive --- anti-vascular endothelial growth factor --- cardiovascular risk factors --- arterial hypertension --- macula-off rhegmatogenous detachment --- superficial perifoveal capillary plexus --- retinal deep perifoveal capillary plexus --- identification --- risk --- Delphi --- STARS® --- food supplement --- bevacizumab --- meta-analysis --- meta-regression --- age-related macular degeneration (AMD) --- comparative therapies --- effectiveness --- intravitreal anti-vascular endothelial growth factor --- treat-and-extend --- pro re nata regimen
Choose an application
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.
Medicine --- aflibercept monotherapy --- polypoidal choroidal vasculopathy --- neovascular age-related macular degeneration --- good baseline visual acuity --- ForeseeHome AMD Monitoring System® --- AREDS2-HOME study --- age-related macular degeneration --- exudation --- optical coherence tomography angiography --- anti-vascular endothelial growth factor --- brolucizumab --- epithelial tear --- optical coherence tomography --- Sorsby’s fundus dystrophy --- Sorsby --- hereditary retinal dystrophy --- choroidal neovascularisation --- macular neovascularization --- anti-VEGF treatment --- long-term FU --- treatment outcome --- emerging treatment --- neovascular age-related macular degeneration (nAMD) --- Vascular Endothelial Growth Factor (VEGF) --- cataract surgery --- clinical trials --- real-world evidence --- AMD --- oct-angiography --- fellow eye --- choriocapillaris --- quiescent macular neovascularization --- ranibizumab --- aflibercept --- anti-VEGF --- visual acuity --- reading acuity --- disease activity --- treatment change --- treat and extend --- switch therapy --- retina --- choroidal neovascularization --- angiogenesis --- meteorin --- therapeutic innovation --- prevention --- nutrients --- lifestyle --- treatment-naive --- anti–vascular endothelial growth factor --- cardiovascular risk factors --- arterial hypertension --- macula-off rhegmatogenous detachment --- superficial perifoveal capillary plexus --- retinal deep perifoveal capillary plexus --- identification --- risk --- Delphi --- STARS® --- food supplement --- bevacizumab --- meta-analysis --- meta-regression --- n/a --- age-related macular degeneration (AMD) --- comparative therapies --- effectiveness --- intravitreal anti-vascular endothelial growth factor --- treat-and-extend --- pro re nata regimen --- Sorsby's fundus dystrophy
Choose an application
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients’ quality of life.
aflibercept monotherapy --- polypoidal choroidal vasculopathy --- neovascular age-related macular degeneration --- good baseline visual acuity --- ForeseeHome AMD Monitoring System® --- AREDS2-HOME study --- age-related macular degeneration --- exudation --- optical coherence tomography angiography --- anti-vascular endothelial growth factor --- brolucizumab --- epithelial tear --- optical coherence tomography --- Sorsby’s fundus dystrophy --- Sorsby --- hereditary retinal dystrophy --- choroidal neovascularisation --- macular neovascularization --- anti-VEGF treatment --- long-term FU --- treatment outcome --- emerging treatment --- neovascular age-related macular degeneration (nAMD) --- Vascular Endothelial Growth Factor (VEGF) --- cataract surgery --- clinical trials --- real-world evidence --- AMD --- oct-angiography --- fellow eye --- choriocapillaris --- quiescent macular neovascularization --- ranibizumab --- aflibercept --- anti-VEGF --- visual acuity --- reading acuity --- disease activity --- treatment change --- treat and extend --- switch therapy --- retina --- choroidal neovascularization --- angiogenesis --- meteorin --- therapeutic innovation --- prevention --- nutrients --- lifestyle --- treatment-naive --- anti–vascular endothelial growth factor --- cardiovascular risk factors --- arterial hypertension --- macula-off rhegmatogenous detachment --- superficial perifoveal capillary plexus --- retinal deep perifoveal capillary plexus --- identification --- risk --- Delphi --- STARS® --- food supplement --- bevacizumab --- meta-analysis --- meta-regression --- n/a --- age-related macular degeneration (AMD) --- comparative therapies --- effectiveness --- intravitreal anti-vascular endothelial growth factor --- treat-and-extend --- pro re nata regimen --- Sorsby's fundus dystrophy
Choose an application
This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles.
Research & information: general --- Biology, life sciences --- subthreshold micropulse laser --- 577-nm laser --- laser fixed parameters --- diabetic retinopathy --- diabetic macular edema --- optical coherence tomography --- autofluorescence --- real-life --- diabetic macular oedema --- visual prognosis --- indicators --- personalized medicine --- age-related macular degeneration --- choroidal neovascularization --- classification --- machine learning --- type 2 diabetes --- retinopathy --- ethnicity --- general practice --- risk factors --- progression --- glycemic gap --- glucose variability --- ETDRS classification --- biomarkers --- phenotypes --- anti-vascular endothelial growth factor --- diabetic retinopathy severity scale --- panretinal leakage index --- neovascular age-related macular degeneration --- anti-VEGF therapy --- retinal thickness --- visual acuity --- variability --- leakage index --- microaneurysms --- intravitreal aflibercept --- neovascularization --- ultra-widefield fluorescein angiography --- retinal imaging --- quantitative biomarkers --- precision medicine --- autoantibodies --- AT1-receptor --- PAR1 --- VEGF-A --- VEGF-B --- VEGF-receptor 2 --- AMD --- complement system --- semi-quantitative multiplex profilin --- mass spectrometry --- C4 --- vitronectin --- factor I --- genetic variants --- metabolites --- HDL --- central area thickness --- biomarker --- microRNA --- anti-VEGF --- retina --- edema --- OCT --- tomography --- microphysiological systems --- blood-neural barriers --- neurovascular unit --- disease modeling --- 3D models --- organ-on-a-chip --- inner blood-retinal barrier --- n/a
Choose an application
This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles.
subthreshold micropulse laser --- 577-nm laser --- laser fixed parameters --- diabetic retinopathy --- diabetic macular edema --- optical coherence tomography --- autofluorescence --- real-life --- diabetic macular oedema --- visual prognosis --- indicators --- personalized medicine --- age-related macular degeneration --- choroidal neovascularization --- classification --- machine learning --- type 2 diabetes --- retinopathy --- ethnicity --- general practice --- risk factors --- progression --- glycemic gap --- glucose variability --- ETDRS classification --- biomarkers --- phenotypes --- anti-vascular endothelial growth factor --- diabetic retinopathy severity scale --- panretinal leakage index --- neovascular age-related macular degeneration --- anti-VEGF therapy --- retinal thickness --- visual acuity --- variability --- leakage index --- microaneurysms --- intravitreal aflibercept --- neovascularization --- ultra-widefield fluorescein angiography --- retinal imaging --- quantitative biomarkers --- precision medicine --- autoantibodies --- AT1-receptor --- PAR1 --- VEGF-A --- VEGF-B --- VEGF-receptor 2 --- AMD --- complement system --- semi-quantitative multiplex profilin --- mass spectrometry --- C4 --- vitronectin --- factor I --- genetic variants --- metabolites --- HDL --- central area thickness --- biomarker --- microRNA --- anti-VEGF --- retina --- edema --- OCT --- tomography --- microphysiological systems --- blood-neural barriers --- neurovascular unit --- disease modeling --- 3D models --- organ-on-a-chip --- inner blood-retinal barrier --- n/a
Choose an application
This reprint includes contributions from leaders in the field of personalized medicine in ophthalmology. The contributions are diverse and cover pre-clinical and clinical topics. We hope you enjoy reading the articles.
Research & information: general --- Biology, life sciences --- subthreshold micropulse laser --- 577-nm laser --- laser fixed parameters --- diabetic retinopathy --- diabetic macular edema --- optical coherence tomography --- autofluorescence --- real-life --- diabetic macular oedema --- visual prognosis --- indicators --- personalized medicine --- age-related macular degeneration --- choroidal neovascularization --- classification --- machine learning --- type 2 diabetes --- retinopathy --- ethnicity --- general practice --- risk factors --- progression --- glycemic gap --- glucose variability --- ETDRS classification --- biomarkers --- phenotypes --- anti-vascular endothelial growth factor --- diabetic retinopathy severity scale --- panretinal leakage index --- neovascular age-related macular degeneration --- anti-VEGF therapy --- retinal thickness --- visual acuity --- variability --- leakage index --- microaneurysms --- intravitreal aflibercept --- neovascularization --- ultra-widefield fluorescein angiography --- retinal imaging --- quantitative biomarkers --- precision medicine --- autoantibodies --- AT1-receptor --- PAR1 --- VEGF-A --- VEGF-B --- VEGF-receptor 2 --- AMD --- complement system --- semi-quantitative multiplex profilin --- mass spectrometry --- C4 --- vitronectin --- factor I --- genetic variants --- metabolites --- HDL --- central area thickness --- biomarker --- microRNA --- anti-VEGF --- retina --- edema --- OCT --- tomography --- microphysiological systems --- blood-neural barriers --- neurovascular unit --- disease modeling --- 3D models --- organ-on-a-chip --- inner blood-retinal barrier --- subthreshold micropulse laser --- 577-nm laser --- laser fixed parameters --- diabetic retinopathy --- diabetic macular edema --- optical coherence tomography --- autofluorescence --- real-life --- diabetic macular oedema --- visual prognosis --- indicators --- personalized medicine --- age-related macular degeneration --- choroidal neovascularization --- classification --- machine learning --- type 2 diabetes --- retinopathy --- ethnicity --- general practice --- risk factors --- progression --- glycemic gap --- glucose variability --- ETDRS classification --- biomarkers --- phenotypes --- anti-vascular endothelial growth factor --- diabetic retinopathy severity scale --- panretinal leakage index --- neovascular age-related macular degeneration --- anti-VEGF therapy --- retinal thickness --- visual acuity --- variability --- leakage index --- microaneurysms --- intravitreal aflibercept --- neovascularization --- ultra-widefield fluorescein angiography --- retinal imaging --- quantitative biomarkers --- precision medicine --- autoantibodies --- AT1-receptor --- PAR1 --- VEGF-A --- VEGF-B --- VEGF-receptor 2 --- AMD --- complement system --- semi-quantitative multiplex profilin --- mass spectrometry --- C4 --- vitronectin --- factor I --- genetic variants --- metabolites --- HDL --- central area thickness --- biomarker --- microRNA --- anti-VEGF --- retina --- edema --- OCT --- tomography --- microphysiological systems --- blood-neural barriers --- neurovascular unit --- disease modeling --- 3D models --- organ-on-a-chip --- inner blood-retinal barrier
Listing 1 - 6 of 6 |
Sort by
|